Advanced Liver Cancer Market Report 2025

This Advanced Liver Cancer market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The advanced liver cancer market size has grown rapidly in recent years. It will grow from $1.89 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth during the historic period can be attributed to several factors, including heightened awareness of liver cancer, a growing patient population, an increased demand for targeted therapies, the expansion of healthcare infrastructure, and a rising preference for minimally invasive treatments.

The advanced liver cancer market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth during the forecast period can be attributed to several factors, including the rising incidence of liver cancer, increased healthcare spending, the growing prevalence of genetic conditions, a higher adoption of precision medicine, and the expanding use of screening and diagnostic tests. Key trends expected during this period include the integration of artificial intelligence in treatments, the development of innovative drugs and therapies, expanding research and development activities, advancements in targeted therapeutics, and a growing demand for personalized medicine.

The increasing prevalence of chronic hepatitis infections is expected to drive the growth of the advanced liver cancer market in the future. Chronic hepatitis infections are persistent viral infections lasting over six months, which can cause liver damage, cirrhosis, or even liver cancer. The rise in these infections is influenced by factors such as insufficient screening and vaccination programs, as well as delayed treatment access. Hepatitis B (HBV) and hepatitis C (HCV) chronic infections are primary causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. Over time, these viral infections lead to liver inflammation, damage, and ultimately cancer. As the incidence of these infections remains high, more individuals are at risk of developing advanced liver cancer. For example, in April 2024, the World Health Organization (WHO) reported that, in 2022, chronic hepatitis B affected 254 million people globally, with 1.2 million new cases diagnosed each year. As a result, the growing prevalence of long-term hepatitis infections is contributing to the expansion of the advanced liver cancer market.

Leading companies in the advanced liver cancer market are focusing on the development of innovative treatments, such as human monoclonal antibodies, to enhance treatment effectiveness and reduce side effects, ultimately improving patient outcomes. A human monoclonal antibody is a laboratory-made molecule that mimics the immune system's ability to fight harmful pathogens or cancer cells. It works by targeting specific antigens on the surface of these harmful entities, triggering an immune response. For example, in October 2022, AstraZeneca, a pharmaceutical company based in the US, announced that the U.S. Food and Drug Administration (FDA) had approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for treating adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. This approval followed the results of the HIMALAYA Phase III trial, which showed that the combination therapy reduced the risk of death by 22% compared to sorafenib. Additionally, about 31% of patients treated with the combination were alive after three years, compared to 20% of those treated with sorafenib. The treatment regimen, known as STRIDE, consists of a single dose of Imjudo followed by regular doses of Imfinzi every four weeks, offering a new therapeutic option for patients with limited treatment alternatives.

In March 2023, the University of Southern California (USC), a private research university based in the US, partnered with Auransa Inc. to further clinical trials for a new targeted treatment for liver cancer. This collaboration combines their expertise to enhance treatment effectiveness for liver cancer and other solid tumors. Auransa Inc., a pharmaceutical company based in the US, specializes in treating advanced liver cancers.

Major players in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced liver cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the advanced liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Advanced liver cancer, or hepatocellular carcinoma (HCC) in its later stages, refers to liver cancer that has either spread beyond the liver or grown large enough to significantly impair liver function. At this stage, the cancer may have invaded nearby blood vessels, lymph nodes, or other distant organs, complicating treatment. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue.

Key diagnostic methods for advanced liver cancer include imaging tests, biopsies, genomic tests, and others. Imaging tests play a vital role in diagnosing, staging, and monitoring hepatocellular carcinoma (HCC) by offering detailed images of the liver and surrounding organs. These tests encompass a variety of technologies such as fluorescent in situ hybridization, next-generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemistry, and more. They are distributed through different channels, including direct tenders, retail sales, and others. These tests are used in several areas, including screening, diagnostics, prognostics, and research, and are employed by various end users, such as hospitals, cancer research centers, academic institutions, diagnostic centers, and ambulatory surgical centers.

The advanced liver cancer market research report is one of a series of new reports that provides advanced liver cancer market statistics including the advanced liver cancer industry global market size regional shares competitors with the advanced liver cancer market share detailed advanced liver cancer market segments market trends and opportunities and any further data you may need to thrive in the advanced liver cancer industry. This advanced liver cancer market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The advanced liver cancer market consists of revenues earned by entities that provide services such as diagnostic services, surgical services, patient support and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced liver cancer market also includes sales of biopsy tools, computed tomography (CT) scans, liver function tests kit, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.